Evidence map›Paper›PMID 39304585›Full record

ArticleAnnals of hematology2024

CAR-T cells for the treatment of pediatric chronic myeloid leukemia in repeatedly relapsed lymphoid blast phase.

Laura-Jane Kramp, Christiane Heydrich-Karsten, Stephanie Sembill, Axel Karow, Thomas Lion, Guranda Chitadze, Meinolf Suttorp, Gunnar Cario, Markus Metzler

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Laura-Jane KrampPediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Medical Center Schleswig-Holstein Kiel, Kiel, Germany.
Christiane Heydrich-KarstenPediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Medical Center Schleswig-Holstein Kiel, Kiel, Germany.
Stephanie SembillPediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, 91054, Erlangen, Germany.
Axel KarowPediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, 91054, Erlangen, Germany.ORCID http://orcid.org/0000-0003-3963-7271
Thomas LionSt. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria.ORCID https://orcid.org/0000-0001-9346-0994
Guranda ChitadzeClinical Research Unit CATCH-ALL (KFO, German Research Foundation), Christian- Albrechts-University of Kiel, Kiel, Germany.ORCID https://orcid.org/0000-0001-9609-4643
Meinolf SuttorpPediatric Hemato-Oncology, Medical Faculty, Technical University Dresden, Dresden, Germany.ORCID https://orcid.org/0000-0002-9522-8838
Gunnar CarioPediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Medical Center Schleswig-Holstein Kiel, Kiel, Germany.ORCID https://orcid.org/0000-0001-8396-0127
Markus MetzlerPediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, 91054, Erlangen, Germany. Markus.Metzler@uk-erlangen.de.ORCID https://orcid.org/0000-0002-4523-1676

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic myeloid leukemia presenting de novo in the blast phase (CML-BP) is a rare diagnosis among pediatric malignancies. We report on a 16-year-old male who presented with CML-BP lymphoid at diagnosis. He was treated with shortened acute lymphoblastic leukemia induction plus the tyrosine kinase inhibitor (TKI) imatinib followed by dasatinib. After achieving molecular remission (MR), hematopoietic stem cell transplantation (HSCT) was performed early after diagnosis. Despite prophylactic dasatinib, he relapsed 3 months later with the kinase domain mutation T315I. Multiple therapeutic approaches including ponatinib, blinatumomab, a 2nd HSCT from a different donor, donor lymphocyte infusions, and high-dose asciminib all resulted in subsequent relapse. Another molecular response was achieved by combining ponatinib plus asciminib with chemotherapy. In this situation, CD19-directed CAR-T cells (Kymriah

Indexed as

Blast CrisisImmunotherapy, AdoptiveLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAdolescentAntineoplastic Combined Chemotherapy ProtocolsHematopoietic Stem Cell TransplantationHumansMaleReceptors, Chimeric AntigenRecurrenceReceptors, Chimeric AntigenBlast phaseCD19 CAR-T cellsChronic myeloid leukemiaRefractory leukemia

Identifiers

PMID39304585
PMCPMC11535078

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.